XORTX Therapeutics Inc. announced the initiation of clinical and commercial manufacturing for XORLO™ (oxypurinol), its proprietary formulation for treating gout, under the XRx-026 program. The company has begun contract production of GMP drug substance using a proprietary synthetic pathway and is working with a partner to manufacture commercial-scale tablets. This activity supports the planned two-part XRX-OXY-102 clinical study and builds validation data intended to support a future New Drug Application (NDA) filing for US FDA marketing approval. The company operates in the pharmaceutical industry, developing therapies for gout and kidney disease.

XORTX Therapeutics terminated its investor relations agreement with IR Agency LLC effective August 7, 2026, rescinding a $2.5 million marketing arrangement originally funded by proceeds from a May 19, 2026 public offering. The company returned the full fee to itself on August 14, 2026 and postponed the program while completing its voluntary delisting from the TSX Venture Exchange, expected September 1, 2026. Additionally, Computershare Investor Services Inc. replaces TSX Trust Company as transfer agent effective September 1, 2026. The filing also corrects a prior omission by disclosing $240,000 in aggregate cash finder’s fees paid for the April 13, 2026 acquisition of Vectus Biosystems Limited’s Renal Anti-Fibrotic Therapeutic Program. XORTX is a late-stage clinical pharmaceutical company developing therapies for gout and progressive kidney disease.

XORTX Therapeutics Inc. filed unaudited condensed interim consolidated financial statements for the six months ended June 30, 2026. The company reported a net loss of $2,499,206 and cash on hand of $994,045. During the period, XORTX completed the acquisition of the VB4-P5 renal anti-fibrotic therapeutic program from Vectus Biosystems Limited for an aggregate deemed value of US$3.0 million, issuing 154,544 common shares and pre-funded warrants valued at $1,871,194. On May 15, 2026, the company raised gross proceeds of $5,000,000 through a public offering of common shares and pre-funded warrants. The filing also notes that XORTX completed a 5-for-1 share consolidation on April 6, 2026, to regain compliance with Nasdaq's minimum bid price requirement. XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for gout and progressive kidney disease.

XORTX Therapeutics Inc. announced that Anthony Giovinazzo is stepping down from the board of directors for personal reasons and to pursue other interests. Dr. Allen Davidoff, co-CEO, thanked Mr. Giovinazzo for his service as chairman of the board over several years, highlighting his contributions to leadership, ethics, and key committees. XORTX Therapeutics Inc. operates in the pharmaceutical industry, focusing on developing innovative therapies for gout and progressive kidney disease.